Valion Bio notifies availability of press release on Entolimod trial at Sheba Medical Center
VBIO•Sheba Medical Center-funded trial to test Entolimod in cancer patients
Valion Bio disclosed a Sheba Medical Center-funded clinical trial to test Entolimod in cancer patients receiving high-dose radiation.
- The study targets radiation-induced neutropenia, positioning Entolimod for a second development path beyond acute radiation syndrome under the FDA Animal Rule.
- The protocol has been finalized; the IRB decision is expected in Q3 2026, the first patient is expected in Q4 2026–Q1 2027, and initial data are expected in early 2027.
